Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christoph Wanner

Showing results (261-270 of 785) with videos related to

Pageof 79
Sort By:
Plos One|November 25, 2015
Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry CardiomyopathyJohannes Krämer, Bart Bijnens, Stefan Störk, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 31, 2007
Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysisVera Krane, Detlef H Krieter, Manfred Olschewski, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 26, 2004
Advanced renal insufficiency in a 34-year-old man with Lowe syndromeLothar Schramm, Andreas Gal, Josef Zimmermann, et al.
Kidney Medicine|April 7, 2022
Validation of a United Kingdom Model to Predict Mortality in Incident Dialysis Patients in the Dialysis Outcomes and Practice Patterns Study Cohort: Introduction of a Clinical Risk ScoreMartin Wagner, David M Kent, Ronald L Pisoni, et al.
Diabetologia|May 2, 2018
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, et al.
Diabetes, Obesity & Metabolism|March 18, 2022
Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individualsRajiv Agarwal, Sibylle Jenny Hauske, David C Wheeler, et al.
Molecular Genetics and Metabolism|December 3, 2010
Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT)Gabor E Linthorst, Dominique P Germain, Carla E M Hollak, et al.
Plos One|May 20, 2021
COVID-19 and the kidney: A retrospective analysis of 37 critically ill patients using machine learningAnna Laura Herzog, Holger K von Jouanne-Diedrich, Christoph Wanner, et al.
Circulation|October 26, 2018
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic ControlSilvio E Inzucchi, Mikhail Kosiborod, David Fitchett, et al.
Diabetes Care|August 28, 2012
Transthyretin predicts cardiovascular outcome in hemodialysis patients with type 2 diabetesAndrea Henze, Katharina M Espe, Christoph Wanner, et al.
Pageof 79

Showing results (261-270 of 785) with videos related to

Sort By:
Pageof 79
Plos One|November 25, 2015
Left Ventricular Geometry and Blood Pressure as Predictors of Adverse Progression of Fabry CardiomyopathyJohannes Krämer, Bart Bijnens, Stefan Störk, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 31, 2007
Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysisVera Krane, Detlef H Krieter, Manfred Olschewski, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 26, 2004
Advanced renal insufficiency in a 34-year-old man with Lowe syndromeLothar Schramm, Andreas Gal, Josef Zimmermann, et al.
Kidney Medicine|April 7, 2022
Validation of a United Kingdom Model to Predict Mortality in Incident Dialysis Patients in the Dialysis Outcomes and Practice Patterns Study Cohort: Introduction of a Clinical Risk ScoreMartin Wagner, David M Kent, Ronald L Pisoni, et al.
Diabetologia|May 2, 2018
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®Bernard Zinman, Silvio E Inzucchi, Christoph Wanner, et al.
Diabetes, Obesity & Metabolism|March 18, 2022
Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in more than 15 000 individualsRajiv Agarwal, Sibylle Jenny Hauske, David C Wheeler, et al.
Molecular Genetics and Metabolism|December 3, 2010
Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT)Gabor E Linthorst, Dominique P Germain, Carla E M Hollak, et al.
Plos One|May 20, 2021
COVID-19 and the kidney: A retrospective analysis of 37 critically ill patients using machine learningAnna Laura Herzog, Holger K von Jouanne-Diedrich, Christoph Wanner, et al.
Circulation|October 26, 2018
Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic ControlSilvio E Inzucchi, Mikhail Kosiborod, David Fitchett, et al.
Diabetes Care|August 28, 2012
Transthyretin predicts cardiovascular outcome in hemodialysis patients with type 2 diabetesAndrea Henze, Katharina M Espe, Christoph Wanner, et al.
Pageof 79